Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The stromal vascular fraction (SVF) cell population is a heterogeneous collection of cells isolated from adipose (fat) tissue, typically obtained through enzymatic digestion and centrifugation of lipoaspirate[1][5][6]. It is not a single defined molecular target or receptor, but rather a mixture containing adipose-derived stem cells (ADSCs), endothelial cells, endothelial progenitor cells, pericytes, immune cells (including T cells, monocytes/macrophages, and lymphocytes), and other stromal cells[3][5][6]. The SVF is characterized by a combination of cell surface markers such as CD34, CD31, CD45, CD73, CD90, and CD105, which are used to distinguish its various cellular subsets[1][3][6]. SVF is mainly employed in regenerative medicine and tissue engineering due to its potential to support tissue repair, stimulate angiogenesis, modulate inflammation, and differentiate into multiple lineages (osteogenic, chondrogenic, adipogenic, etc.)[2][5][6][7]. It has been investigated in various clinical contexts including cardiovascular, neurologic, autoimmune, orthopedic, and degenerative diseases. However, SVF as a whole is not a classical drug target (e.g., receptor or enzyme), but instead serves as a therapeutic cell population or biologic product. Its use raises challenges regarding heterogeneity, standardization of preparation, and long-term safety[6][7]. Because "stromal vascular fraction cell population" refers to a complex mixture of cells, and not a single, defined molecule or drug target, it is not technically considered a therapeutic target such as a receptor, enzyme, or transporter. Instead, it is the source population for multiple regenerative and modulatory cells used experimentally and clinically in cell therapy applications[7].
Paracrine secretion of cytokines, chemokines, and growth factors (e.g., VEGF, TGF-β, HGF) that stimulate regeneration and angiogenesis - Multilineage differentiation of stem/progenitor cells - Immunomodulatory activity via interaction with immune cells[2][5][6][7]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Stromal vascular fraction cell population (SVF).